Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
about
Peripheral cannabinoid receptor, CB2, regulates bone mass.Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesMarijuana use and long-term mortality among survivors of acute myocardial infarctionIs lipid signaling through cannabinoid 2 receptors part of a protective system?Cannabinoids in health and diseaseInterferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic painCrucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic painCB2 receptor-mediated migration of immune cells: it can go either wayThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarinBeta-caryophyllene is a dietary cannabinoidAM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitorsEmerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammationThe endocannabinoid system as an emerging target of pharmacotherapyThe intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humansThe CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetThe cannabinoid CB2 receptor as a target for inflammation-dependent neurodegenerationLipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assaySpecies-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomersAnticancer mechanisms of cannabinoidsCannabinoid and opioid interactions: implications for opiate dependence and withdrawalThe CB2 receptor and its role as a regulator of inflammationAlkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effectsCannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal studyEndocannabinoids, blood pressure and the human heart.Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosisCannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.Targeted zwitterionic near infrared fluorescent probe for improved imaging of type 2 cannabinoid receptors.Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis.Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy.Carboxylesterases: Dual roles in lipid and pesticide metabolism.Cannabinoid receptor 2 signaling does not modulate atherogenesis in miceThe cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages.Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2.CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state.
P2860
Q24536360-A624D16D-4928-4931-9A61-01D056338A1BQ24623282-24A3D20C-A397-4F3E-9125-8B01819AA5B7Q24629571-172D10DA-66C0-4080-B51D-9D81F02FC9D1Q24633122-C9B97190-ED2C-4EC1-95C6-51A30766DB1DQ24633884-8166EF1D-65F1-46FF-BCE7-5FA600229C81Q24634125-DBFEFABB-FBA5-4971-8454-900D9395D0BAQ24634161-4F62C3A0-7412-4CD8-9520-C1C026D92D59Q24643591-FC94F371-ABC6-48D9-9170-58D4879026EFQ24643876-2F34F7A5-17B4-46D7-843E-A204D2FAD1ACQ24645478-78E52F90-2ECB-4A36-A6D9-06F683735D71Q24647198-09C982A4-31C2-4C7B-9C4C-1FE884E2DCC8Q24647850-F3EEAFA7-2C1C-4C54-A5F9-3D2E73EB3FE1Q24648473-BAE78967-34BF-47C3-8F34-A1C4956D27CEQ24648765-A6E6FCB1-D706-4C2C-BB21-EA216E0D7C00Q24650098-29ADF991-7A70-418A-A1D6-A51B90262544Q24651712-97A43FF5-A345-4835-B3A8-7A94775B545AQ24654730-E260585F-FC53-473C-85BA-003B4D14D4F6Q24673335-16218415-C1E8-433B-957D-61E47B2D9ADCQ26750399-61D2B00A-91E4-400A-9449-29D59CC02139Q27000762-A2CD8453-8651-4D97-B3E6-DB8611E2F83BQ28066700-4DED19E4-CB31-4811-B094-626538C7A3FBQ28302804-FCAB81D4-475C-47FD-8D7C-0635997E2B41Q28395270-CE4DAACB-2B9B-470B-AE3A-5CBB61767376Q30368944-7EE177B0-2463-4BCA-84E5-14B1A2E0DE62Q30473707-E5A8EAE7-07B0-45EA-BC90-D8050AA07073Q30506148-1090C10D-FA52-4C0A-BD78-1D48445B3DF2Q30981876-CBE6D74C-52A5-4C2E-B8C9-C23EA06E9A7AQ33464957-553F12F1-1AEB-43BC-861B-EC74BF29044EQ33564023-C2A4BC11-7050-4B8F-9773-937FF8C90D0AQ33604098-54FF79A8-1442-4F25-BD8F-B138483154C0Q33655394-5120130C-C8FC-49F4-B327-D6D3E9771D33Q33687100-66B6FB1E-2DB4-4E41-86EA-20A857F5E8A1Q33847549-AF4B9932-6B7F-4964-92E9-9FB39F247D59Q33865109-5FCAF406-6F1E-4A17-A7ED-25D349BC8CBEQ33889311-6353BA65-8C4F-44F9-86FC-ED154699D30CQ33993080-7484D81F-2B72-48A7-A9D2-A2F21ECFD756Q34054143-B6E0A291-1810-4B9D-9814-F7842795773AQ34098258-343F70AF-9BE8-4234-91FE-4369D0377D27Q34098271-71AE08E1-CEB3-47BA-BABD-733A6738AB04Q34155467-75623817-0BFC-422F-BACA-1820FE594098
P2860
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@ast
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@en
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@nl
type
label
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@ast
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@en
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@nl
prefLabel
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@ast
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@en
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
@nl
P2093
P356
P1433
P1476
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
@en
P2093
Andreas Zimmer
Christian Staub
Fabienne Burger
François Mach
Graziano Pelli
Jean-Louis Frossard
Meliha Karsak
Niels R Veillard
P2888
P304
P356
10.1038/NATURE03389
P407
P577
2005-04-01T00:00:00Z
P5875
P6179
1040131238